Events
Events Search and Views Navigation
September 2021
Let’s Chat About … the importance of the patient voice in rare disease
Free
Sofia Sees Hope is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We’ve developed the series with those living with LCA and IRDs in mind, but we invite all members of our community, including those in research, industry, and the regulatory communities to join any of the sessions, as we look ahead to a common goal of advancing treatments for rare retinal disease. Jill Dolgin, PharmD, Head…
Find out more »October 2021
Let’s Chat About … CRISPR and gene editing technology
Free
Sofia Sees Hope is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We've developed the series with those living with LCA and IRDs in mind, but we invite all members of our community, including those in research, industry, and the regulatory communities to join any of the sessions, as we look ahead to a common goal of advancing treatments for rare retinal disease. Monica Roy is Vice…
Find out more »Bidding in the Dark
Yes, we are asking you to tap your inner adventurer and philanthropist and bid on items that you might not have all the details around. We call it, Bidding in the Dark. For all of the items, we've provided some descriptions, so you're not completely in the dark. For some of the items, there are hints. For a few of the items, we've attempted to simulate what the item might look like to someone who has a rare retinal disease.…
Find out more »November 2021
Let’s Chat About … ProQR’s work in treatments for inherited retinal disease
Sofia Sees Hope is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We've developed the series with those living with LCA and IRDs in mind, but we invite all members of our community, including those in research, industry, and the regulatory communities to join any of the sessions, as we look ahead to a common goal of advancing treatments for rare retinal disease. Daniel de Boer, Founder and…
Find out more »